The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced nasopharyngeal carcinoma (NPC): Pooled cohort data from phase 1a/1b trials.
 
Hongyun Zhao
No Relationships to Disclose
 
Yan Huang
No Relationships to Disclose
 
Wenfeng Fang
No Relationships to Disclose
 
Yuxiang Ma
No Relationships to Disclose
 
Yang Zhang
No Relationships to Disclose
 
Xiao-Li Wei
No Relationships to Disclose
 
Yanhua Yang
No Relationships to Disclose
 
Wei Yang
No Relationships to Disclose
 
Furong Liu
No Relationships to Disclose
 
Zuan Lin
No Relationships to Disclose
 
Jianing Li
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Innovent Biologics
Speakers' Bureau - AstraZeneca; BeiGene; HenRui; Innovent Biologics; Roche China
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Junshi Pharmaceuticals (Inst); QiLu Pharmaceutical (Inst)